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Summary: A complete description of a component-binding radioimmunoassay of rat urinary kaliikrein is presented.
Each step of the radioimmunoassay was evaluated and optimized. The problems encountered in the development of
the assay are discussed; this may be a guide to the treatment of similar problems in the development of a comparable
component-binding radioimmunoassay. Protocols are presented for performance of the assay with [3H]-labelled or
[125Ill-labelled rat urinary kaliikrein. Radioimmunoassay and immunodoublediffusion data suggested that rat plasma
indeed contains an antigen similar to glandular kallikrein. However, quantitation of the antigen by the direct radio-
immunoassay must await appropriate developments for efficient dissociation and/or denaturation of interfering
substances.
Radioimmunassay für Kallikrein in Rattenharn und Identifizierung des homologen Enzyms im Plasma
Zusammenfassung: Ein komponentenbindender Radioimmunassay für Kallikrein in Rattenharn wird vollständig und
ausfuhrlich beschrieben. Jeder Schritt des Radioimmunassay wurde ausgewertet und optimiert. Die bei der Entwick-
lung der Bestimmung aufgetretenen Probleme werden diskutiert; dies kann eine Anleitung für die Behandlung ähn-
licher Problerne bei der Entwicklung eines vergleichbaren komponentenbindenden Radioimmunassay sein. Protokolle
für die Durchführung der Bestimmung mit 3H- bzw. 125I-markiertem Kallikrein aus Rattenharn werden beschrieben.
Daten des Radioimmunassay und der Immundoppeldiffusion weisen daraufhin, daß Rattenplasma wirklich ein dem
glandulären Kallikrein ähnliches Antigen enthält. Die quantitative Bestimmung des Antigens mit einem direkten
Radioimmunassay erfordert jedoch noch die Entwicklung geeigneter Verfahren für eine wirksame Abtrennung und/
oder Denaturierung von Störsubstanzen.
Introduction Recently Oza et al. (5) produced antibodies of rat urin-
M „. „ , , ary kallikrein. These antibodies produced rapid inhibitionThe excretion of kallikrein in urine has been reported to
 rf .^^  ^  fc ^  and fa ^  Preliminary data on
be altered in certain forms of hypertensive cardiovascular
 g ^ .^  onent_binding RIA have been ted
diseases (1). However, the physiological or pathological ^ ^ ^ ^  ^
 devel nt of
role of this hypotensive enzyme system m hypertension .^^
 conditions fof ±Q assay In addition> the assay
is not understood.
 is employe(1 in conjunction with the Ouchterlony tech-
Kallikrein activity has been measured by its ability to „jque to identify glandular kallikrein in plasma,
hydrolyze certain acylated argiriine esters or by its ability
to form kinins from kininogen (2). However, the estero-
lytic assay lacks specificity and the proteolytic assay is Methods and Results
subject to many variables often resulting in imprecise ^ ^ .^  ^ ^^ ^
 isolated a$ describe<j previously (5) by
data. Moreover, the inhibitors of kallikrein and kallikrein- DEAE-cellulose, affinity (Trasylol-Sepharose) and Sephadex
like enzymes, which are generally present in tissues and G-100 chromatography. Pure kailikrein was [3HJ-labeiled with
body fluids, can indeed interfere in the functional assays. ^l^S^^^^^StSiXS^
Thus, a kallikrein-binding radioimmunoassay (RIA) may
 dex Q_IOQ gel fiitration (7). The purified, immunoreactive
prove useful not only for the resolution of some of the f 3HJkaUikrein had a specific radioactivity of 947.2 TBq/mol
* . ,.
 /<5 ./, . . f u-„n ;„+* rt,* mrdo (25.6 Ci/mmol) (Packard Tri-carb scintillation counter with effi-debated issues (3,4) but also for- probing into the mole- ^^
 Q/f ^  ^  % and ft wa$ $tored frozen ^ Q 05 mol/1
cular mechanism of secretion of precursor and/or active Tris-HCl buffer, pH 7.4, containing 1 g/1 bovine serum albumin
forms of kallikrein in urine, lymph and plasma. (assay buffer).
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Although the RIA was standardized mainly with the [3H]kalli-
krein, the possibility of increasing the sensitivity of the assay by
using [125I)kallikrein was investigated. Pure kallikrein was iodi-
nated in 20 Mg batches with 37 MBq carrier-free 125I (New Eng-
land Nuclear Corp.) according to the procedure of Hunter &
Greenwood (8). Immunoreactive [12*I)kallikrein was purified
by Sephadex G-100 gel filtration as detailed in a prevous paper
(7). The specific radioactivity was calculated to be 2.37 kBq//ig
(64 MCi/Mg) or approx. 1 iodine atom per molecule of kallikrein.
Antikallikrein
Rabbit anti-rat urinary kallikrein serum was that reported by
Oza et al. (5). A single batch of high-titer antiserum was used
throughout these studies.
Double antibody
The initial supply of goat anti-rabbit immunoglobulin (IgG type)
serum (double antibody) was purchased from Miles Laboratories,
Inc., Elkhart, Ind. However, the potency of the commercial anti-
serum varied from batch to batch, requiring ^standardization of
the assay conditions. Therefore, the double antibody was raised
in a goat and, once again, a single pool of high-titer anti-rabbit
immunoglobulin (IgG) serum was used throughout these studies.
Separation of free from antibody-bound [3H]kallikrein
The formation of antigen-antibody conjugate was first assessed
by the filtration of [3 H]kallikrein and antigen-antibody reaction
mixtures on a Sephadex G-100 column (1.5 X 12 cm). The co-
lumn was equilibrated in the assay buffer and calibrated by fil-
tration of 1.0 mg Blue Dextran 2000 (Pharmacia Fine Chemicals,
Piscataway, N.J.). Following this, approx. 4000 counts/min of
[3 HJkallikrein was passed through the column.
The [3H]kallikrein emerged in a uniform peak at about
two times the void volume of the column as shown in
figure la. Nonetheless, a distinction could not be made
between the control ([3H]kallikrein and non-immune
serum) and experimental ([3HJkallikrein and anti-kalli-
krein serum) incubation mixtures when they were passed
through the same column (see fig. la). Perhaps the non-
immune and immune sera contained protein inhibitors
ofkallikrein(9).
In another experiment, aliquots of normal rabbit serum and anti-
kallikrein serum were adjusted to pH 3.0 with 1 mol/1 HC1,
allowed to stand for 30 min at 25 °C and readjusted to pH 7.4
with 1 mol/1 NaOH (acid pH treatment). Both the sera were then
heated to 56 °C for 3 h and centrifuged at 3079 g for 30 min
(heat treatment). The supernatants (treated normal rabbit serum
or anti-kallikrein) were used in appropriate dilutions.
As shown in figure Ib, a marked distinction was now ob-
tained in the filtration profiles of the control and experi-
mental reaction mixtures. As expected, the incubated re-
action mixture of [3H]kallikrein and normal rabbit serum
emerged as a single peak at twice the void volume while
the incubated reaction mixture of [3H]kallikrein and anti-
kallikrein emerged as two peaks (see fig. Ib). The first
peak emerging with the void volume corresponded to the
[3H]kallikrein-anti-kaUikrein while the second peak emerg-
ing at twice the void volume corresponded to the unreac-
ted [3H]kallikrein. In view of this, all of the sera employ-
ed in this study were given acid pH and heat treatment
prior to their use in the RIA.
In a typical experiment, the anti-kallikrein was also tested direct-
ly and after acid and heat treatments for fraction of binding with
approximately 4000 counts/min of [3H]kallikrein. In 1:25,000













Fig. 1. Sephadex G-100 gel filtration of [3H]kallikrein (o) and of
incubation mixtures of [3 HJkallikrein with normal rabbit
serum (x) and anti-kallikrein serum (o) in the upper half
V of the figure. In the lower half V are shown the elution
profiles of the same incubation mixtures in which the nor-
mal and antikallikrein serum were used after acid pH and
heat treatment s described in the text. The column was
1.5 X 12 cm; the void volume is shown by the arrow.
0.472 conjugation. Thus, the treated antibody had little or no
effect on the formation of a workable conjugate in the radioim-
munoassay.
Optimum concentration of anti-kallikrein and double
antibody
The anti-kallikrein serum was adjusted to four different dilutions
to obtain fractions of 0.70, 0.50, 0.30 and 0.20 binding of
[3H]kallikrein. Seven reactions were set up for each dilution
of anti-kallikrein serum in which the double antibody was
added in increasing amounts from 20 to 100 ìÀ.
As shown in figure 2a, 20 ìÀ double antibody were found
to be optimal for complete precipitation of [3H]kallikreiii-
anti-kallikrein conjugate when the initial binding was
0.48 (see reaction no. 2). As shown in figure 2b, the effec-
tive dilution of anti-kallikrein serum was found to be
1:25000 for a desirable initial binding of 0.48. In the
subsequent experiments, anti-kallikrein serum was there-
fore used in a final dilution of 1 : 25 000, and the double
antibody in a final dilution of 1 : 30 (20 ìÀ in 0.6 ml
total volume).
Optimal time of first incubation .
The fraction of maximal binding was studied as, a function of
time of incubation.
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Dilution of ont i -kol l ikrem serum
Fig. 2. l3H)KaUikrein-anti-kallikrcin complex formed with the di-
lutions 1 : 25500 (2), 1 : 50000 (3), and 1 : 100000 (4)
of the antiserum. The antigen-antibody complex was pre-
cipitated with different amounts of double antibody. In
reactions 1 and 2, the optimal concentration of the double
antibody was found to be 20 ìÀ (inset a). The fraction of
initial binding with different dilutions of anti-kallikrein
serum is shown in inset *b\ The experiment was performed
at pH 7.4; the time of the first incubation was 2 h and
that of the second incubation was 18 h.
The data presented in figure 3 indicated that over 0.95 of
binding occurred within 2 h of incubation of [3H]kalli-
krein with the anti-kallikrein serum at 25 °C. In a similar
study, the optimal time for second incubation, following
the addition of double antibody, was found to be 18 h at
4°C.
Optimal pH
The RIA was performed in the assay buffer adjusted to pH 7.0,
7.4, 8.0 and 8.5.
As shown in figure 4, satisfactory displacement was ob-
tained at pH 7.0-7.4. In assays routinely performed at
pH 7.4 the coefficient of intra-assay variation (n = 6) was
found to be 7.6%. Furthermore, when a single urine was
analyzed for 7 consecutive days, the kallikrein concen-
tration was found to be 7.2 ± 0.3 mg/1 (mean ± S.E.M.).
ProtocoLfor the radioimmunoassay
[3HlKallikrem was suitably diluted in the assay buffer so as to
contain approx. 4000 counts/mm in 0.1 ml. Anti-kallikrein se-
rum was d uted l : 5000 in the assay buffer which in addition
contained 1 : 4000 dilution of the treated normal rabbit serum
for the enrichment of non-immune immunoglobulins. The reac-
tion mixture contained 0.1 ml l3Hlkallikrein (approx. 4000
counts/min), 0.1 ml of a 1: 5000 dilution of anti-kallikrein serum,
unlabelled pure kallikrein (usually 5-200 ng), or the unknown
sample, and the balance of buffer to a total volume of 0.5 ml.
The reaction mixture was incubated 2 h at 25 C, followed by
addition of 100 ìÀ of 1 : 5 dilution of double antibody to each
Incubation time [h]
Fig. 3. The fraction of maximal binding shown at different times
of the first incubation. The time of the second incubation
was kept constant at 18h.
1.00
40 ÈÏ 120 160
Kall ikre in Ing]
200
Fig. 4. The radioimmunoassay curve obtained at pH 7.4 (o) com-
pared with experimental values obtained at pH 7.0 (x),
8.0 (D), and 8.5 (Ä).
tube. The assay tubes were further incubated 18 h at 4 °C; the
resulting precipitate of l3Hlkallikrein-anti-kallikrein-double an-
tibody complex was collected by ccntrifugation at 3079 g for
30 min in a refrigerated centrifuge. The supernatant (0.3 ml),
containing free pHlkallikrcin, was mixed with 10 ml of solubi-
lizcr 118% BBS-3 (Beckman Instruments, Inc., Fullerton, Calif.),
42 ml liquiflour Q.S. made up to 1 liter with toluene) and count-
ed for at least 10 min. Total counts were determined by substi-
tuting anti-kallikrein serum with normal rabbit serum. Duplicate
estimations were made and the unknown sample was interpolat-
ed from a standard plot of fraction of initial binding versus the
amount of added kaUikrein. The standard curve was constructed
by a computer program which plotted fraction of initial bind-
ing versus the amount of added kallikrein (10).
RIA with [l2sI]Kallikrein
The assay conditions were identical to those already described,
except that the anti-kallikrein serum was used in a dilution of
1 : 40000, and the first incubation was performed for 4 h.
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The standard plot, in figure 5, enabled determination of
1 to 10 ng of kallikrein. Furthermore, 1 ng gave a frac-
tion of initial binding of 0.89 (fig. 5) as opposed to
10 ng that was required to obtain a fraction of initial
binding of 0.90 (fig. 4) in the case of [3H]kallikrein.
Thus, as expected, the sensitivity was increased approx-
imately ten fold by using [125I]kallikrein as a tracer.
Forty-six rat urine samples were analyzed for kallikrein
by the direct RIA and for kinin-generating activity by a
kinin RIA (l 1). A correlation coefficient of 0.81 was ob-
tained (7).
Identification of glandular kallikrein-like antigen in
plasma
Blood was collected by decapitation of rats (normal or 24 hours
after bilateral nephrectomy) in 200 units of heparin. After centri-
fugation, the plasma samples of individual rats were kept frozen.
The RIA was employed to test normal rat plasma either directly,
after serial dilutions (e.g. 1 : 2, 1 : 4,1 : 8 .... etc.), or after aci-
dification and heat denaturation, as described in a previous sec-
tion.
Normal rat plasma was capable of displacing the antigen-
antibody complex, but the displacement curve (see figure
6) was not parallel to the standard curve. After a serial
dilution of 1 : 1024, the antigen concentration was in-
creased almost 20 fold. Although dilution invariably
caused an increase in the concentration of radioimmuno-
assayable kallikrein, the extent of dilution differed from
one sample to the other. After acidification and heat de-
naturation of normal rat plasma, the antigen concentra-
tion was reduced by almost 90%. This treatment was
therefore not suitable for selectively denaturing interfer-
ing substance(s). Although dilution of normal plasma ap-
peared promising, further efforts to quantitate plasma
antigen were defferred until such time as a uniform tech-
nique could be devised for physical separation or selec-
tive denaturation of the interfering substance(s).
i.ook-
2 4 6 8 1 0
Kallikrein (ng]
Fig. 5. A standard radioimmunoassay curve using [3H]kallikrein
as a radiolabelled antigen.
I I I
40 80 120 160 200 '
' Kallikrein (ngj or
Normal rat plasma and rat urine [ìÀ]
Fig. 6. Comparison of the displacement profiles of rat plasma (x)
and rat urine with the standard plot (o).
Owing to the above limitation stated, immunodoublediffusion
(12) was employed to qualitatively identify the antigen in nor-
mal and nephrectomized rat plasma. The center well contained
undiluted rabbit anti-rat urinary kallikrein serum and peripheral
weUs contained either normal rat plasma or nephrectomized rat
plasma in a range of zero to 2048 fold dilutions.
A distinct precipitation band (line of identity) was ob-
tained when the normal rat plasma was either undiluted
or diluted 1 : 2. In the case of nephrectomized rat plasma,
a much stronger line of identity was obtained when the
plasma was diluted 1 : 16 to 1 : 32. Using nephrecto-
mized rat plasma, it was expected that the precipitin band
would disappear if the antigen was secreted by the kid-
ney. On the contrary, the concentration of the antigen
was enhanced, suggesting that kidney may be involved in
the filtration of glandular kallikrein secreted into the cir-
culation.
As shown in figure 6, high displacements were obtained
with 5—30 ìÀ of rat urine. Normal rat urine contains
kallikrein in the concentration of 5-7 mg/1 urine. Thus,
the nonparallelity of urine aliquots, iri this experiment,
was due to a concentration which was about five fold
higher than the range of the standard curve. In. other ex-
periments, a perfect par llelity was in fact obtained when
the urine sample was diluted 1 : 5 or 1 : 10 in the RIA
buffer.
Discussion
Since the initial recognition by Elliot &Nuzum (13) of
the suppression of urinary kallikrein in essential hyperten-
sion, many reports have appeared which either confirmed
(14) or extended (1) this inexplicable finding. Recently,
evidence has been adduced (14,15) to suggest the role of
kallikrein in diuresis and natriuresis. Nonetheless, it re-
mains to be resolved whether the alterations in the excre-
tion of this enzyme are deleterious, beneficial, or inci-
dental. It also remains to be determined whether the im-
plications of kallikrein release are local o'fare systemic.
j. Ciin. Chem. Cliri. Biochem. / Vol. 19,1981 / No. 10
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It may be possible to resolve some of these issues with the
use of a component-binding assay.
In addition to forming an antigen-antibody conjugate,
the radiolabelled kallikrein was found to bind with a pro-
tein component of the rabbit serum (see fig. 1). The na-
ture of the component is not known at present, but nor-
mal serum is known to contain certain inhibitors (16).
Since serum inhibitors of kallikrein can be denatured by
acid pH and/or heating at 56 °C (9), it is conceivable that
the unspecific binding, encountered in the present study,
was due to one of the inhibitors.
It is evident from the present data that the anti-kallikrein
serum employed in the present study was of a higher qua-
lity. In 1 : 25000 dilution (fig. 2), the antiserum gave
0.48 binding with radiolabelled enzyme. Almost all of
this binding occurred in 2 h of incubation (fig. 3). The
consistency of the displacement curve obtained at pH
7.0-7.4 (fig. 4) was indeed of help in the measurement
of kallikrein at the physiological pH of rat plasma.
In immunodouble diffusion tests (5), the anti-kallikrein
serum was found to react with rat urine and homogenates
of salivary gland, pancreas and kidney, but not with
bovine trypsin, or dog or human urine. Recently Proud
et al. (17), using a direct radioimmunoassay, showed that
salivary, urinary and pancreatic kallikrein, and pancreatic
prekallikrein have identical immunological behaviour.
The direct immunoassay of an enzymic protein is parti-
cularly advantageous since it utilizes the antigenic pro-
perty of the enzyme and not the affinity of the enzyme
for its substrate or inhibitor. Thus, theoretically it should
be possible to determine the concentration of the enzyme
in the presence of its inhibitor as long as the inhibitor is
not large enough to bury antigenic determinants. In the
case of ä tiypsin radipimmunoassay (18), serum inhibi-
tors were found not to interfere in the determination of
circulating trypsin. In the present study, rat urine samp-
les were analyzed directly for kallikrein concentration
because no apparent differences were found between dia-
lyzed and undialyzed samples.
In a few experiments, the first incubation of radiolabelled
kallikrein and antikallikrein was performed for 18 h in-
stead of 2 h with no obvious improvement in the profile
of the standard plot. Furthermore, it was evident that the
radioimmunoassay could be performed with [125I]kalli-
krein or [3H]kallikrein depending upon the requirement
for a higher sensitivity (see fig. 5) or durability of the en- Acknowledgements
zyme. The biological relevance of the assay was demon-
strated by a high correlation of 0.81 between the present
direct assay and a functional assay (7).
There is evidence in the literature which suggests that
glandular kallikrein may be released in the systemic cir-
culation (19-21); More recently, Rabito et al. (22) and
Fink et al. (23) have adduced immunological evidence
for the presence of glandular kallikrein in plasma. How-
ever, contrary reports (24, 25) have indicated that glan-
dular kallikrein is not normally found in the plasma. The
objective of the present work was to qualitatively identi-
fy such an antigen if it is indeed detectable by immuno-
logical and/or radioimmuiiological techniques. The pre-
liminary experiments, reported here, indicated that glan-
dular kallikrein is indeed present in the normal rat plasma.
The concentration of this antigen is increased 24 hours
after nephrectomy suggesting that kidneys may be able
to filter such an antigen. The question of whether the
antigen is radioimmunoassayable is not adequately an-
swered by the present experiments. The displacement
profile with plasma antigen was not parallel to the stand-
ard curve (see fig. 6). Such a displacement may be due to
interference with the availability of the antigenic determi-
nants of a specific antigen. The fact that the concentra-
tion of this antigen was increased by dilution is compel-
ling and it tends to support a thesis that the displacement
was due to a specific antigen (glandular kallikrein) which
was partially masked by interfering substances of the plas-
ma. Nonetheless, a final identification must await isola-
tion and characterization of the antigen. Recently,
Geiger et al. (27) have acheived isolation of glandular
kallikrein from human plasma.
The significance of glandular kallikrein in plasma is not
known. However, it has been reported that plasma con-
tains 10% of a high molecular weight kininogen and 90%
of a low molecular weight kininogen (26). Thus, if glan-
dular kallikrein should be secreted into the circulation, a
large amount of its preferred substrate (low molecular
weight kininogen) is indeed available. Nonetheless, the
secreted enzyme must compete for the substrate in the
presence of a large amount of interfering substance(s),
which are normally present in the plasma (16).
In conclusion, a detailed account of the development of
a direct RIA of rat urinary kallikrein has been presented.
Using this assay and the immunodoublediffusion tech-
nique, data have been obtained which suggest the release
of glandular kallikrein in plasma. Furthermore, prelimi-
nary evidence is suggestive that the kidneys may be able
to filter glandular kallikrein which is released in the circu-
lation. The findings are in agreement with the data of
Fink et al. (23) who investigated renal filtration of pig
pancreatic kallikrein in dogs.
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J. Qin. Chem. Clin. Biochem. / Vol. 19, 1981 / No. 10
1038 <^za: 'Radioimmunpassay of rat urinary kallikrein
References
1. Margoüus, H. S., Geller, R. G., Pisano, J. J., & Sjoedsma, A. 17. Proud, D., Baüey, G. S., Nustad, K., & Gautwik, K- M. (1977),
(1971), Lancet//, 1063-1065. Biochem. J. 167, 835-838.
2. Trautschold, I. (1970), Handb. Exp. PharmacoL 25, 52-81. 18. Temler, R. S. & Felber, J. P. (1976), Biochim. Biophys. Acta
3. GeUer, R. G., Margoüus, H. S., Pisano, J. J.s & Keiser, J. R. 445, 720-728.(1972) Circ. Res. 31, 857-861. 19. Roblero, J., Croxatto, H., Garcia, R., Cörthorn, J., & DeVito,
4. Adetuyibi, A. & Mills, I. H. (1972), Lancet //, 203-207. E. (1976), Am. J. PhysipL 231,1383-1389.
5. Oza, N. B., Amin, V. M., McGregor, R. K., Scicli, A. G., & 20. Fink, E., Seifert, J., Guttel, C. (1978), Z. Anal. Chem. 290,
Carretero, 0. A. (1976), Biochem. Pharmacol. 25,1607-1612. 183-188.
6. Oza, N. B., Amin, V. M., Gandolfi, R., Yanari, S., & Carretero, 21. Nustad, K., Orstavik, T. B., Gautvik, K. M., & Pierre, J. V.
O. A. (1976), Fed. Proc. 35, 693. (1978), Gen. PharmacoL 9,1-9.
7. Oza, N. B. (1977), Biochem. J. 167, 305-307. 22. Rabito, S., Amin, V. M., Scicli, A. G., & Carretero, 0. A.
8. Hunter, W. M. & Greenwood, F. C. (1962), Nature 194, (1979), Fed. Proc. 38, 686.
495_496. 23. Fink, E., Geiger, R., Witte, J., Biedermann, S., Seifert, J.,
9. Vogel, R. & Werle, E. (1970), Handb. Exp. Pharrhacpl. 25, & Fritz, H. (1980) In: Enzymatic release of vaspactive pep-
213-249. tides (Gross, F., & Vogel, H. G., eds.) Raven Press, New
10. Rodbard, D., Rayford, P. L., Cooper, J. A., & Ross, G. T. York, P. 101.
(1968), J. Clin. EncrinoL Metab. 28,1412-1418. 24. Pisano, j. J. (1875), In Proteases and Biological Control,
11. Carretero, 0. A., Oza, N. B., Piwonska, A., Ocholik, T., & Cold Spring Harbor Laboratory, Cold Spring Harbor, N. .,
Scicli, A. G. (1976), Biochem. Pharmacol. 25, 2265-2270. 199-222.
12. Ouchterlony, O. (1949), Acta Path. Microbiol. Scand 26, 25. Vinci, j. M., Gill, J. R,, Bowden, R. E., Pisano, J. J., Izzo, J.
507-512. L., Radter, N., Taylor, A. A., Zusman, R. M., Bartter, R. C.,
13. Elliot, A. H. & Nuzum, F. R. (1934), Endocrinol. 18, & Keiser, H. R. (1978), J. Clin. Invest. 61, 1671-1682.
462-474. 26. Hashimoto, K., Wanka, J., Kohn, R. N., Wilkens, J. J., Steger,
14. Croxatto, H. R. & San Martin, M. (1970), Experientia 26, R-, & Back, N. (1976), Adv. Exp. Med. BioL 70, 245-254.
1216-1217. 27. Geiger, R., Chlausnitzer, B., Fink, E., & Fritz, H. (1980),
15. Mills, I. H. & Ward, P. E. (1975), J. PhysioL 246, 695-707. Hoppe-Seyler's Z. Physiol. Chem. 361,1795-1803.
16. Harpel, P. C. (1971), J. Clin. Invest. 50, 2084-2090.
Narendra B. Oza, Ph. D.
Associate Research Professor of Medicine
and Associate Professor of Biochemistry
Boston University School of Medicine
University Hospital
75 East Newton Street
Boston, Mass. 02118
U.S.A.
J. Clin. Chem. Clin. Biochem. / Vol. 19,1981 / No. 10
